A Phase 4, Open-Label, Efficacy and Safety Study of Apokyn for Rapid and Reliable Improvement of Motor Symptoms in Parkinson Disease Subjects With Delayed Onset of L-Dopa Action
Latest Information Update: 16 Aug 2023
At a glance
- Drugs Apomorphine (Primary) ; Levodopa (Primary) ; Levodopa/carbidopa (Primary) ; Trimethobenzamide (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Acronyms AM-IMPAKT
- Sponsors US WorldMeds
- 23 Jun 2015 Results presented at the 1st Congress of the European Academy of Neurology.
- 18 Jun 2015 Results for secondary endpoints in patients treated in the early morning presented at the 19th International Congress of Parkinson's Disease and Movement Disorders.
- 18 Jun 2015 Results (secondary analysis) presented at the 19th International Congress of Parkinson's Disease and Movement Disorders.